Protein-based therapeutics can activate the adaptive immune system, leading to the production of neutralizing antibodies and the clearance of the treated cells mediated by cytotoxic T cells. Here, we show that the sequential use of immune-orthogonal orthologues of CRISPR-associated protein 9 (Cas9) and adeno-associated viruses (AAVs) evades adaptive immune responses and enables effective gene editing using repeated dosing. We compared total sequence similarities and predicted binding strengths to class-I and class-II major histocompatibility complex (MHC) proteins for 284 DNA-targeting and 84 RNA-targeting CRISPR effectors and 167 AAV VP1-capsid-protein orthologues. We predict the absence of cross-reactive immune responses for 79% of the DNA-targeting Cas orthologues-which we validated for three Cas9 orthologues in mice-yet we anticipate broad immune cross-reactivity among the AAV serotypes. We also show that efficacious in vivo gene editing is uncompromised when using multiple dosing with orthologues of AAVs and Cas9 in mice that were previously immunized against the AAV vector and the Cas9 cargo. Multiple dosing with protein orthologues may allow for sequential regimens of protein therapeutics that circumvent pre-existing immunity or induced immunity.
P rotein therapeutics, including protein-based gene therapy, have several advantages over small-molecule drugs. They generally serve complex specific functions and have minimal offtarget interference on normal biological processes. However, one of the fundamental challenges to any protein-based therapeutic is the interaction between the therapy and the adaptive immune system. Neutralization of the treatment by circulating antibodies that are released by B cells after activation and clearance of treated cells by CD8 + cytotoxic T lymphocytes (CTLs) creates a substantial barrier to effective protein therapies [1] [2] [3] [4] . Although the delay in the adaptive immune response to novel proteins may allow sufficient time for the initial dose to work for some applications, subsequent doses face faster and stronger secondary immune responses owing to the presence of memory T cells and B cells. Gene transfer studies have also shown that immune responses of the host against the delivery vector and/or therapeutic transgene can eliminate treated cells, therefore limiting the efficacy of the treatment [5] [6] [7] [8] [9] [10] [11] .
A common approach to circumventing these issues has been to use human proteins or to humanize proteins by the substitution of non-human components 12, 13 . However, this approach is limited to a small set of therapeutic proteins that naturally occur in humans or closely related species. Furthermore, although the humanization of proteins can result in a product that is substantially less immunogenic, they still carry an immunological risk 13 . Another way to circumvent an immune response to protein therapeutics is the removal of immunogenic T cell epitopes [14] [15] [16] . Once these epitopes are identified, substitution of key amino acids may reduce the immunogenicity of the protein because modification of critical anchor residues can abrogate binding to MHC molecules and prevent antigen presentation. However, this can prove difficult owing to the high level of diversity at the human leukocyte antigen (HLA) loci. As epitope engineering must account for the substrate specificity of each different HLA allele, therapeutics would probably require unique modifications for each patient. Although epitope deletion and/or mutation has been successfully applied to several proteins 16, 17 , this can only preserve protein function when limited to small numbers of HLA alleles that are not representative of the full diversity of the HLA. Structural modifications, such as PEGylation, have also been known to reduce immunogenicity by interfering with antigen-processing mechanisms. However, there is evidence that polyethylene glycol (PEG)-specific antibodies are elicited in patients who are treated with PEGylated therapeutic enzymes [18] [19] [20] [21] .
Furthermore, protein therapies often require repeated treatments due to degradation of the protein, turnover of treated cells or-in the case of gene therapy-reduced expression of the transgene 22, 23 . This provides an even greater challenge because repeated exposure to the same antigen can elicit a more robust secondary immune response 24 , which may completely inhibit subsequent dosage or even sensitize the immune system to antigens that remain from the initial exposure. To facilitate efficacious repeat protein therapies, we propose the use of orthologous proteins of which the function is constrained by natural selection, but the structure of which is subject to diversification by forces such as genetic drift. An orthologue, given sufficient sequence divergence, will not cross-react with the immune response generated by exposure to the other orthologues, allowing subsequent doses to avoid neutralization by existing antibodies and treated cells to avoid clearance by activated CTLs.
As a case study for exploring this approach, we focused on the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system, which is perhaps the most anticipated therapeutic for gene editing [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Comparative genomics has demonstrated that Cas9 proteins are widely distributed across bacterial species and have diversified through an extensive evolutionary history [36] [37] [38] [39] [40] . Although there may be pre-existing immunity to Cas9 proteins from pathogenic or commensal species [41] [42] [43] , we hypothesized that this diversity could provide a mechanism to circumvent the induction of immunological memory by using orthologous Cas9 proteins for each treatment.
An additional important consideration is the immunogenicity of the delivery vehicle or administration route for the Cas9 and associated guide RNA (gRNA). In this regard, AAVs have emerged as a highly preferred vehicle for gene delivery because they are associated with low immunogenicity and toxicity 8, 9 , which promotes transgene expression 44, 45 and treatment efficacy. Despite the relatively low immunogenicity of AAV vectors, antibodies against both the capsid and transgene may still be elicited 10, [46] [47] [48] [49] [50] [51] [52] . Moreover, the prevalence of neutralizing antibodies against AAVs in the human population 53 and cross-reactivity between serotypes 54 remains a hurdle for efficacious AAV therapy. Although AAVs were initially considered to be non-immunogenic owing to their poor transduction of antigen-presenting cells (APCs) 55 , it is now known that they can transduce dendritic cells 56 and trigger innate immune responses through Toll-like receptor (TLR) signalling pathways 57 . The ability to transduce dendritic cells is dependent on the serotype and genome of the AAVs and may be predictive of overall immunogenicity 58 . A previous study exploring the utility of the AAV-Cas9 system observed a humoral immune response to both AAV and Cas9, as well as an expansion of myeloid and T cells in response to Cas9 52 , highlighting the need to confront this issue while further developing gene therapies.
To evaluate the immune orthogonality of AAV-delivered CRISPR-Cas systems, we analysed 284 DNA-targeting and 84 RNA-targeting CRISPR effectors and 167 AAV VP1 orthologues. By comparing the total sequence similarity of these peptides and their predicted binding strengths to class I and class II MHC molecules, we constructed graphs of immune cross-reactivity and computed cliques of proteins that are orthogonal in immunogenicity profiles. Although MHC epitopes do not predict antibody epitopes, the induction of the more powerful memory response is primarily dependent on reactivation of memory B cells with help from memory T cells through the presentation of antigens on class II MHC molecules 59, 60 . We then experimentally confirmed our immunological predictions by assaying treated mice for induction of proteintargeting antibodies and cytotoxicity mediated by T cells against AAV and Cas9 proteins. Finally, we demonstrated-in multiple contexts-that consecutive dosing with immune-orthogonal orthologues circumvents the inhibition of effective gene editing caused by immune recognition of the AAV vector and Cas9.
results
Immune response to AAV and Cas9. One of the major obstacles for treatment using sequential gene therapy is the presence of neutralizing antibodies against the delivery vehicle and the transgene cargo that are induced by the first administration of the therapy (Fig. 1a ). To determine the humoral immune response kinetics to AAV-CRISPR therapeutics (Fig. 1b )-focusing as an exemplar on the AAV8 capsid and the Cas9 transgene-we initially injected C57BL/6J mice retro-orbitally with 1 × 10 12 viral genomes (VG) of AAV8 carrying the Staphylococcus aureus Cas9 (SaCas9) transgene, targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), which is a promising gene target that when disrupted can reduce low-density lipoprotein levels and protect against cardiovascular disease. Consistent with a previous study 61 , mice showed reduced PCSK9 serum levels as early as one week after injection due to successful SaCas9-mediated gene editing, which was sustained for the entire duration of the experiment (four weeks; Fig. 1c ). We noted that a subset of the mice developed IgG1 antibodies against the SaCas9 protein ( Fig. 1d ). Additionally, mice developed humoral immunity to the AAV8 capsid within one week after injection ( Fig. 1e ). Finally, we also confirmed a response of CD4 + T cells against AAV8 and SaCas9 for a subset of the predicted MHCII epitopes on these proteins using an enzyme-linked immunospot (ELISPOT) analysis ( Supplementary Fig. 1 ). To evaluate the feasibility of multiple dosing with AAV-Cas9, we next investigated whether immune-orthogonal sets of AAV and Cas9 orthologues exist.
Identifying immune-orthogonal proteins. Natural selection produces diverse structural variants with conserved function in the form of orthologous genes. We assayed the relevance of this diversity for immunological cross-reactivity of 284 DNA-targeting and 84-RNA targeting CRISPR effectors ( Supplementary Table. 1) and 167 AAV orthologues (Supplementary Table 2 ) by first comparing the overall amino acid sequence similarities of these CRISPR effectors and AAV orthologues, and second, using a more specific constraint of comparing how their respective amino acid sequences are predicted to bind MHC class I and II molecules ( Fig. 1f ). From these analyses we first obtained an estimate of the comprehensive immune overlap among Cas and AAV orthologues on the basis of the sequence level and, second, a more stringent estimate of the predicted immune overlap on the basis of predicted MHC binding ( Fig. 1g ,h, Supplementary Fig. 2 ). Using sequence-level clustering and clique finding methods, we defined many sets of Cas9 orthologues that contained up to 9 members with no 6-mer overlap ( Supplementary Fig. 3 ). Notably, on the basis of MHC-binding predictions, we found-among the set of DNA-targeting Cas proteins (240 Cas9 and 44 Cpf1 proteins)-that 79% of pairs are predicted to have non-cross-reacting immune responses, that is, they are predicted to be orthogonal in immune space ( Fig. 1g ). By contrast, among AAV capsid (VP1 protein) orthologues, we did not find full orthogonality up to the 14-mer level, even when restricting predictions with MHC-binding strengths (Fig. 1h ); this probably reflects the strong sequence conservation and shorter evolutionary history of AAVs 62 . This analysis suggests-consistent with previous observations 63, 64 -that exposure to one AAV serotype can induce broad immunity to all AAVs, which presents a considerable challenge to AAV delivery methods because some serotypes are prevalent in human populations. Despite the most divergent AAV serotype (AAV5) showing the least shared immunogenic peptides, there remain tracts of sequences that are fully conserved within the VP1 orthologues. As expected, predicted immune cross-reaction negatively correlates with phylogenetic distance ( Supplementary Fig.  4 ), although there is a substantial variation that was not captured by that regression, suggesting that MHC-binding predictions can refine the choice of sequential orthologues beyond phylogenetic distance alone.
Confirming humoral immune orthogonality among Cas9 proteins.
To test our immunological predictions and to establish the utility of this approach, we focused on a five-member clique containing the ubiquitously used Streptococcus pyogenes Cas9 (SpCas9) in addition to the well-characterized S. aureus Cas9 ( Supplementary  Fig. 3 ). To determine whether either of these proteins have crossreacting antibody responses, we injected mice with 1 × 10 12 VG of either AAV8 or AAVDJ capsids containing SaCas9 or SpCas9 transgenes by retro-orbital injections and collected serum at day 0 (before injection) and periodically over 4-6 weeks ( Fig. 2a ). SpCas9specific antibodies were detected in the plasma of all mice injected with SpCas9 (n = 6) but, notably, SpCas9-specific antibodies were not detected in mice injected with SaCas9 (n = 12; Fig. 2b ). Half of the mice injected with AAVs carrying the SaCas9 transgene (n = 12) developed detectable antibodies against SaCas9, whereas none of the mice injected with AAVs carrying the SpCas9 transgene (n = 6) developed an antibody response against SaCas9. These results were confirmed in an independent study in which SpCas9-specific antibodies-but not SaCas9-specific antibodies-were detected in the plasma of mice injected with AAV-SpCas9 (n = 12). These mice were injected retro-orbitally with 1 × 10 12 VG of AAV8-SpCas9 or AAVDJ-SpCas9 and also received an additional intramuscular injection of 1 × 10 11 VG at week 4 ( Fig. 2c ). Taken together, our data confirms that SpCas9 and SaCas9 have humoral immune orthogonality. As an additional step, we tested another Cas9 orthologue a, Mice were exposed to antigens by retro-orbital injections at 1 × 10 12 VG per mouse. Serum was collected before injection on day 0, and at multiple points over the course of 4-6 weeks. b, Levels of anti-SpCas9 antibodies generated in mice injected with either SpCas9 (n = 6) or SaCas9 (n = 12), and levels of anti-SaCas9 antibodies generated in mice injected with either SpCas9 (n = 6) or SaCas9 (n = 12). Data are mean ± s.e.m. Each data point represents an individual mouse. c, Levels of anti-SpCas9 and anti-SaCas9 antibodies generated by mice injected retro-orbitally 1 × 10 12 VG on day 0 and intramuscularly with 1 × 10 11 VG on week 4 with AAV8-SpCas9 (n = 12; left) or AAVDJ-SpCas9 (n = 12; right). Data are mean ± s.e.m. Each data point represents an individual mouse. d, Levels of anti-AAV8/AAVDJ/AAV2/AAV5 antibodies generated in mice injected with either AAV8 or AAVDJ (n = 4 for all panels), or with either AAV2 or AAV5 (n = 6 for all panels except for the AAVDJ serum ELISA at the week 6 time point for which n = 5). Data are mean ± s.e.m. Each data point represents an individual mouse.
from Campylobacter jejuni, which is useful for AAV-based delivery owing to its small size. Mice injected retro-orbitally with 1 × 10 12 VG AAV8-CjCas9 (n = 12) showed no significant humoral response to SpCas9 or SaCas9 after 4 weeks ( Supplementary Fig. 5 ), confirming immune orthogonality for a set of three unique Cas9 orthologues.
Confirming broad immune cross-reactivity among AAV serotypes.
AAVs are becoming a preferred delivery vehicle owing to their ability to avoid the induction of a strong CD8 + T cell response; however, the presence of neutralizing antibodies remains a substantial barrier to successful application of AAV therapies. Consistent with previous results 63 , we found shared immunogenic peptides among all human AAV serotypes ( Supplementary Fig. 6 ). We confirmed the lack of orthogonality for two serotypes-AAV8 and AAVDJin which we found that antibodies produced in mice injected with AAV8 or AAVDJ react to both AAV8 and AAVDJ antigens ( Fig. 2d ). Our analysis suggests that there are no two known AAVs for which exposure to one would guarantee immune naivety to another across all MHC genotypes. However, immune cross-reaction could be minimized through the use of AAV5 64, 65 , the most phylogenetically divergent serotype. Our predictions identify only one highly immunogenic peptide that is shared between AAV5 and the commonly used AAV2 and AAV8 in the mouse model (although several other shared peptides with mild MHC affinity exist). We confirmed this by analysis using enzyme-linked immunosorbent assays (ELISAs), in which mice injected with AAV2 did not elicit antibodies against AAV5 and AAV8, and mice injected with AAV5 did not elicit antibodies against AAVDJ and AAV8 ( Fig. 2d ).
Overcoming immune barriers to effective gene editing.
Having demonstrated that AAV-Cas9 viruses elicit an immune response in the mouse model and that the humoral responses to SpCas9 and SaCas9 do not cross-react, we then performed a two-step dosing experiment to test whether these immune responses inhibit the efficacy of multi-dose gene editing, and whether using immuneorthogonal orthologues in sequence can avoid immune-mediated inhibition of gene editing ( Fig. 3a , Supplementary Fig. 7 ). For this experiment we used BALB/c mice to verify and characterize the immune response in two independent strains. The first round of dosing contained no gRNA and served to immunize the mice against the second dose, which contained an active AAV8-SaCas9 containing a Pcsk9-targeting gRNA, allowing us to directly measure genome editing efficiency by sequencing, as well as measure the levels of serum PCSK9 as a phenotypic readout for therapeutic efficacy. We also measured IgG responses to all AAV and Cas9 used in the experiment. As expected from previous preclinical studies on AAV therapies, previous exposure and humoral immunity to AAV8 (AAV8-mCherry) abolished the effectiveness of subsequent gene editing when using AAV8 as the delivery vector (AAV8-SaCas9). Importantly, this effect was not seen with previous exposure to AAV5 (AAV5-mCherry), and subsequent dosing with AAV8-SaCas9 resulted in strong genome editing and Pcsk9 knockdown similar to the effects of AAV8-SaCas9 treatment in naive mice (Fig. 3b,c) . Although we do not necessarily expect the orthogonality that was observed between AAV8 and AAV5 to carry over into the human setting, here it allowed us to specifically test the effects of the immune response to the cas9 cargo with minimal interference from the AAV delivery vector. Mice that were first immunized against SaCas9 using AAV5 showed a 35% reduction in the level of editing, a 38% reduction in the decrease in serum levels of PCSK9 and a wider variation between mice compared with the unimmunized (saline-treated) mice. This may reflect a weak immune response to SaCas9 in our mouse model and/or a domination of private (individual) T cell responses to SaCas9. IgG ELISAs revealed that only a subset of mice immunized with AAV5-SaCas9 developed an antibody response. We correlated the level of serum antibodies induced on SaCas9 immunization with the efficiency of Pcsk9 editing after the second dose, and we found that mice with a stronger antibody response showed lower editing efficiency ( Supplementary  Fig. 7b ). By contrast, we found that mice first dosed with AAV5-SpCas9 showed robust editing similar to that in naive mice, suggesting that the predicted and measured immune orthogonality of SpCas9 and SaCas9 can be harnessed to circumvent immune barriers to gene editing.
To replicate these findings in a different context, and to verify that immunity to Cas9 can specifically create a barrier to effective gene therapy, we conducted a slightly modified immunization experiment. We used a Cas9 protein vaccine combined with complete Freund's adjuvant (CFA) in emulsion as the initial dose, thereby immunizing a Cas9-specific primary response independently of AAV ( Fig. 3d ). Subsequent dosing with AAV8-SaCas9 targeting PCSK9 recapitulated the results of AAV-based immunization, showing that previous exposure to the SaCas9 protein-but not SpCas9-significantly reduced the effectiveness of SaCas9based gene editing (Fig. 3e,f) . We also tested the ability of CFA-Cas9 immunized mice to clear injected splenocytes pulsed with immunogenic Cas9 epitopes. We observed specific clearance of Cas9-pulsed cells 3.5 weeks after immunization, demonstrating that anti-Cas9 T cells can specifically recognize and kill cells that present Cas9 epitopes ( Supplementary Fig. 8 ).
Taken together, anti-AAV and anti-Cas9 immunity represents a potential obstacle to therapeutic efficacy, and the use of immune orthogonal AAVs and Cas proteins-by bypassing immune recallenables effective gene editing using repeated administrations of these therapeutic modalities. Fig. 3 | engineering re-dosing with immune orthogonal orthologues. a, Mice were initially immunized with saline, AAV8-mCherry, AAV5-mCherry, AAV5-SaCas9 or AAV5-SpCas9 with no gRNA. After 4 weeks, the mice were given a second dose of saline or AAV8-SaCas9 with a gRNA targeting Pcsk9. Serum was collected before the first injection and again during each subsequent week for 8 weeks. Mice were exposed to antigens by retro-orbital injections at 1 × 10 12 
discussion
The use of protein therapeutics requires ways to evade the immune response of the host. Cas9, for example, has prokaryotic origins and can evoke a long-lived T cell response 42, 52 that may lead to the clearance of transduced cells. Furthermore, circulating antibodies can neutralize the AAV vector and prevent efficient transduction after repeated doses. Immunosuppressive drugs could mitigate some of these aspects, but not without considerable side effects, and these drugs are not applicable to patients in poor health [66] [67] [68] [69] . Similar to what has been done using cancer-targeting antibody therapeutics 70 , the SpCas9 protein could be deimmunized by swapping highimmunogenicity domains. This is a promising approach; however, it will be complex and laborious as we anticipate tens of mutations to achieve stealth, which might often result in a reduction in activity and a less effective therapy overall.
Another consideration is that various applications of the CRISPR system will have substantially different consequences on the immune system. For example, compare genome-editing applications-in
Week 0: inject first AAV-Cas9 (no gRNAs)
Week 4: inject second AAV-Cas9 (gRNA targeting Pcsk9)
Week 8: assay Saline Saline Saline
AAV8-SaCas9
AAV8-mCherry
AAV5-mCherry
AAV5-SaCas9
AAV5-SpCas9
First dose
Second dose PBS PBS PBS
CFA-PBS

CFA-SaCas9
AAV8-SaCas9
CFA-SpCas9
AAV8-SaCas9
First dose Week 0: inject CFA + Cas9
Week 1: inject AAV-Cas9 (gRNA targeting Pcsk9) which only transient expression of Cas9 is required-with cases of gene regulation (CRISPR interference or CRISPR activation), in which continuous Cas9 expression is required. Although ongoing expression applications will have to continuously contend with T cell surveillance, genome editing with transient expression may not be compromised by a primary T cell response if Cas9 expression is lost before CTL activation and clonal expansion. Building on this advantage, we note that promising new techniques may achieve stable gene regulation by transient-that is, hit-and-run-approaches using epigenome editing 71 . Despite this, efficacious single-dose therapies may require high titres, especially in cases such as Duchenne muscular dystrophy, in which systemic delivery is needed. Such high doses may lead to toxicity issues, as demonstrated in a recent study of high-dose AAV9 delivery in rhesus macaques 72 . Multiple lower non-toxic doses delivered sequentially have the potential to achieve high transduction efficiency but must contend with a stronger and faster secondary adaptive immune response that is mediated by memory T cells and B cells.
To circumvent this issue, here we developed a framework to compare protein orthologues and their predicted binding to MHCI and MHCII by checking a sliding window of all k-mers in a protein for their presence in another, focusing on peptides that we predicted would bind to at least one MHC allele. Through this analysis, we identified cliques of Cas9 proteins that are immune orthogonal. On the basis of these predictions, specific T cell responses from one orthologue would not cross-react with another orthologue of the same clique, preventing the reactivation of CD8 + cytotoxic T cells, as well as the CD4 + helper T cells necessary to reactivate memory B cells. We confirmed these results through ELISAs and verified that three well-characterized Cas9 proteins (SpCas9, SaCas9 and CjCas9) are immune orthogonal. Finally, we demonstrated in multiple contexts that consecutive dosing with the same AAV or Cas9 orthologue can lead to diminished editing efficacy that can be overcome with the use of immune orthogonal orthologues. Therefore, we expect that proteins belonging to the same clique can be used sequentially without eliciting responses of memory T cells and B cells.
An important caveat is that each sequential orthologue should also be immune orthogonal to the pre-existing immune repertoire. Recent research has begun to explore pre-existing immunity to SpCas9 and SaCas9 [41] [42] [43] in human donors. One potential repository of Cas9 to which humans may not have any pre-existing immunity is in the genomes of extremophiles. However, although humans have probably not been exposed to these organisms previously, their Cas9 proteins may nevertheless be closely related to commensal or pathogenic species, and therefore immune orthogonality to pre-existing immunity must be rigorously evaluated. To explore this issue, we categorized 240 Cas9s orthologues on the basis of their species of origin as commensal, pathogenic, environmental or extremophile, and compared the immune orthogonality between these groups ( Supplementary Fig. 9 ). Preliminary analysis suggests that there may be Cas9 proteins from extremophile species that are divergent enough to be orthogonal to pre-existing immunity, even when taking into account both pathogens and commensals. Many more candidates will probably be discovered as we continue cataloguing microbial diversity in a variety of environments using metagenomic approaches. Alongside this process, more diverse Cas9 proteins must be tested and studied to determine whether-and under what conditions-they will be usable in a mammalian setting.
Owing to the importance of AAVs as a delivery agent in gene therapy, we also analysed AAV serotypes through our MHCI and II comparison framework and have demonstrated that no two AAVs are predicted to be entirely immune orthogonal. However, with a known HLA genotype, it may be possible to define a personalized regimen of immune orthogonal AAVs using serotypes that are already defined. For instance, use of AAV5 minimizes immune cross-reactivity in mice and non-human primates, as demonstrated by a recent study in which chimaeric-AAV5-immunized mice and non-human primates successfully received a second dose of treatment with AAV1 65 . However, in the human setting, we predict that there may be substantially more immune overlap between AAV5 and other AAVs. It has also been shown that memory B cells heavily contribute to the antibody response to similar but not identical antigens 73 , indicating that partial orthogonality may not be sufficient. Our analysis suggests that creating a pair of globally orthogonal AAV capsids for human application would require more than ten mutations in one of the two proteins. This hypothetical orthogonal AAV capsid presents a substantial engineering challenge, as it requires mutating many of the most conserved regions to achieve immune orthogonality.
Although we characterize the adaptive immune response to both the AAV VP1 and Cas9 proteins, it is not expected that these will induce the same type or kinetics of response due to the differing nature of the antigens. The mice receive VP1 protein in the form of a viral capsid, as contrasted with Cas9 in the form of DNA. The delivery of AAV capsids is expected to produce a strong antibody response through the canonical MHC class II pathway. It may also induce a CTL response through MHC class I presentation by transduction of APCs or cross-presentation of endocytosed viral proteins.
Alternatively, the Cas9 transgene is expressed as protein only once inside a transduced cell, and therefore could be expected to induce both an antibody and CTL response through two separate but not mutually exclusive mechanisms. One potential avenue is that a subset of AAVs transduce APCs, an event that has been previously observed to occur 56 . After expression, Cas9 may be presented on class I MHC molecules through the canonical pathway or presented on class II MHC molecules after being encapsulated in autophagosomes (a substantial fraction of MHCII-bound peptides is derived from internal proteins through autophagy) 74 . Another potential mechanism involves transduced non-APCs expressing Cas9 and subsequently undergoing apoptosis or necrosis. APCs then scavenge these dying cells, presenting the Cas9 proteins found within on class II MHC molecules through the canonical pathway or on class I MHC molecules through cross-presentation-a process that is important for anti-viral immune responses.
Previous research has identified that MHC affinity is highly dependent on anchor residues at both ends of its binding pocket 75 . Residue diversity is more tolerated in the centre of the binding pocket-although these residues may have the greatest effect on antigen specificity-as it is thought that these residues are central to the interaction with the T cell receptor (TCR). A comparison of the number of orthologous pairs in 9-mer space with the number of predicted orthologous pairs on the basis of class-II-binding predictions indicates that only approximately 65% of 9-mer peptides serve as appropriate MHC class II binding cores, even across the thousands of HLA-2 combinations that we explored here. This undersampling of peptide space by MHC molecules probably reflects the requirement for hydrophobic anchor residues in the MHC binding pocket and leaves room for protein deimmunization through mutation of immunogenic peptides to ones that never serve as MHC binding cores. However, achieving these mutations while preserving protein function has proven to be difficult even for small numbers of HLA alleles, and remains a major protein engineering challenge. New technologies for directly measuring TCR affinity with MHCpresented antigens 76 will also further clarify the key antigenic peptides contributing to the immune response, and will be useful to inform approaches here.
We also note some limitations to our study. We mainly used two inbred mouse strains-C57BL/6J and BALB/c-as our model; these strains of mice have limited MHC diversity 77 and might not recapitulate other human immunological features, such as differences in antigen processing and presentation. Our use of highly conservative models of potential human immunity suggests that any immune barriers to gene editing that we observe here could be substantially magnified in the human setting. We therefore attempted to measure the human T cell response using an IFNγ ELISPOT assay for a subset of the predicted MHCI and MHCII peptides ( Supplementary  Tables 3 and 4 ), the results of which corroborated recent studies of pre-existing immunity to SpCas9 and SaCas9 in humans 16, 41, 42 that showed measurable effector and regulatory T cell responses. We observed a low CD4 + T cell response against specific MHCII peptides for mice injected with SaCas9 in our C57BL/6J model ( Supplementary Fig. 1 ). One promising approach is to harness the ability of regulatory T cells to promote a more tolerogenic immune response to therapeutic proteins 42 . Additionally, B cell epitopes can also be predicted and incorporated into immune orthogonality analysis. However, these are more difficult to predict because B cell epitopes may be both linear and conformational. Advances and further validation of these in silico models will enable better predictions in the future [78] [79] [80] [81] [82] . In our study, initial immunization doses were not delivered with a gRNA, therefore, Cas9 produced inside the cell or delivered as a protein will be in the apo-Cas9 conformation. This could result in different B cell epitopes compared with the gRNA-bound Cas9 complex, as the three-dimensional conformations are substantially different. Note, however, that this should not affect MHC-presented peptides, and therefore not affect T cell responses. Finally, recent research has indicated that spliced-host and pathogen-derived peptides created by proteasomal processing might make an important contribution to MHC class I peptides 83 . It is unclear how this could affect cross-recognition of the proteins that we predict to be immune orthogonal, but it provides a mechanism by which cross-recognition of substantially different foreign antigens might result from very-short antigenic peptides spliced to the same host protein; however, we think that this is improbable owing to the large number of possible spliced peptides between the antigen and entire host proteome.
Overall, we believe that our framework provides a potential solution for efficacious gene therapy, not only for Cas9-mediated genome engineering, but also for other protein therapeutics that might necessitate repetitive treatments. Although the use of this approach still requires mitigation of the primary immune response-particularly antibody neutralization and CTL clearance-we expect that epitope deletion and low-immunogenicity delivery vectors, such as AAVs, will mitigate this problem, and the potential for repeated dosage will reduce the need for very high first-dose titres and efficiency.
Methods
Computational methods. k-mer analyses. For Cas9, we initially chose 91 orthologues that were cited in exploratory studies cataloguing the diversity of the Cas9 protein 36, 39, 40, [84] [85] [86] , including several that are experimentally well characterized. We subsequently expanded our analysis to a total of 240 Cas9 orthologues and 44 Cpf1-Cas12a orthologues for DNA-targeting CRISPR-associated effector proteins, and 84 RNA-targeting CRISPR-associated effectors including Cas13a, Cas13b and Cas13c. For AAVs, we analysed 167 sequences, focusing on all 13 characterized human serotypes as well as one isolate from rhesus macaque (rh32), one engineered variant (DJ) and one reconstructed ancestral protein (Anc80L65). We then compared the total sequence similarity (immunologically uninformed) between these peptides as well as comparing their predicted binding to class I and class II MHC molecules (immunologically informed). Immunologically uninformed sequence comparisons were carried out by checking a sliding window of all contiguous k-mers in a protein for their presence in another protein sequence with either zero or one mismatch.
MHC binding predictions. An immunologically informed comparison was performed in a similar fashion but using only those k-mers that were predicted to bind to at least 1 of 81 HLA-1 alleles using netMHC v.4.0 87 for class I (alleles can be found at http://www.cbs.dtu.dk/services/NetMHC/MHC_allele_names. txt) and at least 1 of 5,620 possible MHCII molecules on the basis of 936 HLA-2 alleles using netMHCIIpan v.3.1 88 for class II (alleles can be found at http://www. cbs.dtu.dk/services/NetMHCIIpan-3.1/alleles_name.list). We compared the use of netMHC with alternative immune epitope prediction platforms methods, such as the Immune Epitope Database (https://www.iedb.org) 89 , and found very strong agreement across software. Ultimately, we chose netMHC owing to the larger number of HLA alleles it supports. Sequences were defined as binding if the predicted affinity ranked in the top 2% of a test library of 400,000 random peptides, as suggested in the software guidelines. The generation of immune orthogonal cliques was performed using the Bron-Kerbosch algorithm. In brief, a graph was constructed with each orthologue as a vertex, in which the edges are defined by the number of shared immunogenic peptides between the connecting vertices. Sets of proteins in which every pair in the set is immune orthogonal constitute a clique.
Phylogenetics and species classification. For phylogenetic analyses, protein sequences were aligned using MUSCLE, and distance was calculated using the BLOSUM 62 matrix excluding insertions and deletions. A phylogeny of AAV serotypes was created using neighbour joining on major serotype sequences. Categorization of Cas9 orthologues into commensal, pathogenic, environmental and extremophile species of origin was performed by assessing the source of the sample sequence. Sequences that were isolated from species that had been observed in humanassociated samples were classified as pathogenic if they had been reported to cause disease (this included species that are normally commensal, but opportunistically pathogenic), otherwise, they were reported as commensal. Sequences from species that are not known to be associated with the human microbiome were classified as environmental unless the species was uniquely isolated from extreme environments including geothermal vents, deep anoxic groundwater, fossil fuel deposits and polar ice.
Experimental methods. Vector design and construction. Split-SpCas9 AAV vectors were constructed by sequential assembly of corresponding gene blocks (IDT) into a custom synthesized rAAV2 vector backbone 90, 91 . The first AAV contains a gRNA driven by a human RNA polymerase III promoter, U6 and a N-terminal Cas9 (NCas9) construct fused to an N-intein driven by a CMV promoter, as well as a polyadenylation (polyA) signal. The second AAV cassette contains a CMV-driven C-terminal Cas9 (CCas9) construct fused to a C-intein as well as a polyA signal. gRNA sequences were inserted into NCas9 plasmids by cloning oligonucleotides (IDT) encoding spacers into AgeI cloning sites using Gibson assembly. pX601-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA was a gift from F. Zhang (Addgene plasmid, 61591).
AAV production. AAV2/8, AAV2/2, AAV2/5 and AAV2/DJ virus particles were produced by HEK293T cells using the triple transfection method and purified with an iodixanol gradient 92 . Confluency at transfection was between 80% and 90%. Medium was replaced with prewarmed medium 2 h before transfection. Each virus was produced in 5 × 15 cm 2 plates, and each plate was transfected with 7.5 μg of pXR-capsid (pXR-8, pXR-2, pXR-5 or pXR-DJ), 7.5 μg recombinant transfer vector and 22.5 μg of pAd5 helper vector using polyethylenimine (PEI; 1 μg μl −1 linear PEI in 1× DPBS pH 4.5, using HCl) at a PEI:DNA mass ratio of 4:1. The mixture was incubated for 10 min at room temperature and then applied dropwise onto the medium. The virus was collected after 72 h and purified using an iodixanoldensity-gradient ultracentrifugation method. The virus was then dialysed with 1× PBS (pH 7.2) supplemented with 50 mM NaCl and 0.0001% of Pluronic F68 (Thermo Fisher) using 100 kDa filters (Millipore) to a final volume of around 1 ml, and quantified by qPCR using primers specific to the inverted terminal repeat (ITR) region, against a standard (ATCC VR-1616). The primers used were as follows: AAV-ITR-F, 5′-CGGCCTCAGTGAGCGA-3′; and AAV-ITR-R, 5′-GGAACCCCTAGTGATGGAGTT-3′.
Animal studies. All animal procedures were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the University of California, San Diego. All mice were acquired from the Jackson Laboratory. AAV injections were performed in adult male C57BL/6J or BALB/c mice (10 weeks old) through retro-orbital injections using 1 × 10 12 VG per mouse.
CFA immunizations. CFA immunizations were prepared by mixing CFA (Sigma-Aldrich) with 5 μg Cas9 protein or PBS at a 1:1 ratio using two syringes connected by an elbow joint to create an even emulsion. Then, 200 μl of CFA emulsion was injected subcutaneously into the flanks of adult mice.
ELISA. Levels of serum PCSK9 were measured using the Mouse Proprotein Convertase 9/PCSK9 Quantikine ELISA kit (R&D Systems) according to the manufacturer's guidelines. In brief, serum samples were diluted 1:200 in Calibrator diluent and allowed to bind for 2 h onto microplate wells that were precoated with the capture antibody. Samples were then sequentially incubated with PCSK9 conjugate followed by the PCSK9 substrate solution with extensive intermittent washes between each step. The amount of PCSK9 in serum was estimated colorimetrically using a standard microplate reader (BioRad iMark).
ELISA for Cas9 and AAV was performed as follows. Recombinant SpCas9 protein (PNA Bio, CP01), or SaCas9 protein (ABMgood, K144), was diluted in 1× coating buffer (Bethyl), and 0.5 μg was used to coat each well of 96-well Nunc MaxiSorp plates (ab210903) overnight at 4 °C. For AAV experiments, 1 × 10 9 VG of AAV2, AAV5, AAV8 or AAVDJ in 1× coating buffer was used to coat each well of 96-well Nuc MaxiSorp plates. Plates were washed three times for 5 min with 350 μl of 1× wash buffer (Bethyl) and blocked with 300 μl of 1× BSA blocking solution (Bethyl) for 2 h at room temperature. The wash procedure was repeated. Serum samples were added at 1:40 dilution and plates were incubated for 5 h at 4 °C with shaking. Wells were washed three times for 5 min and 100 μl of HRP-labelled goat anti-mouse IgG1 (Bethyl; diluted 1:100,000 in 1% BSA blocking solution) was added to each well. After incubating for 1 h at room temperature, wells were washed four times for 5 min, and 100 μl of TMB substrate (Bethyl) was added to each well. Optical density at 450 nm (OD 450 ) was measured using a plate reader (BioRad iMark).
NGS quantification of editing. Genomic DNA was extracted from samples of mouse livers using a DNA extraction kit (Qiagen). A 200 bp region containing the target cut site of the Pcsk9 gene was amplified by PCR using 0.5 μg DNA (around 100,000 diploid genomes) as the template. Libraries were prepared using NEBNext Illumina library preparation kit and sequenced using an Illumina HiSeq. Each sample was sequenced to a target depth of 100,000 reads. Adaptors were trimmed from resulting fastqs using AdapterRemoval 93 and non-homologous end-joining-repaired cleavage events resulting in a mutation were quantified using CRISPResso 94 .
Splenocyte clearance assay. Splenocyte clearance assays were performed similarly to previous research 95 . In brief, spleens from adult C57BL/6J mice were collected and treated to remove erythrocytes and dead cells. These cells were then diluted to 1 × 10 7 cells ml −1 and split into two pools, one of which was pulsed for 40 min with a pool of the 30 most immunogenic T cell epitopes in SpCas9 (according to our predictions) at 1 μg ml −1 each and labelled with the CellTrace Violet fluorescent dye (ThermoFisher). The other pool was pulsed with a matching volume of DMSO, and labelled with the green fluorescent dye CFSE (ThermoFisher). A 1:1 mixture of these cells were then retro-orbitally injected into naive or CFA-immunized mice at week 1 or week 3.5 at 3-6 × 10 7 cells per mouse. Spleens from these mice were collected 16-20 h later, treated to remove erythrocytes and analysed by flow cytometry to assess the degree of specific clearance of the CTV + cells that were pulsed with Cas9 peptides.
Statistics. PCSK9 ELISA data from immunization experiments ( Fig. 3 , Supplementary Fig. 7) were normalized per mouse to the average of the first 4 weeks of the experiment (during which time no active dose was given), and then these data were analysed using a two-way repeated-measures ANOVA to account for both time and group membership as independent variables. Post hoc Tukey's tests were used to compare across groups at each time point as shown in Fig. 3c .
Epitope prediction and peptide synthesis. The MHC-binding peptides for our mouse model were predicted using the netMHC v.4.0 and netMHCIIpan v.3.1 online software with the alleles H-2-Db and H-2-Kb for class I and H-2-IAb for class II. For MHCII, the top 10 peptides by percentile binding for SpCas9 and SaCas9 and top 5 peptides for AAV8 and AAVDJ were selected for synthesis by Synthetic Biomolecules as crude materials. For MHCI, we selected the top 20 peptides for SpCas9 and SaCas9 and the top 10 for AAV8 and AAVDJ. All of the peptides were dissolved in DMSO with a concentration of 40 mg ml -1 and stored at −20 °C.
IFNγ ELISPOT assay. CD8 + T cells were isolated from splenocytes using magnetic bead positive selection (Miltenyi Biotec) 6 weeks after virus infection. A total of 2 × 10 5 CD8 + T cells were stimulated with 1 × 10 5 lipopolysaccharide blasts loaded with 10 µg of individual peptide in 96-well flat-bottom plates (Immobilon-P, Millipore) that were coated with anti-IFNγ monoclonal antibodies (clone AN18, Mabtech) in triplicate. Concanavalin A was used as positive control. After 20 h of incubation, biotinylated anti-mouse IFNγ monoclonal antibodies (R4-6A2; Mabtech), followed by ABC peroxidase (Vector Laboratories) and then 3-amino-9ethylcarbazole (Sigma-Aldrich) were added to the wells. Responses are expressed as number of IFNγ spot-forming cells (SFC) per 1 × 10 6 CD8 + T cells.
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Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code Data collection netMHC software used to predict peptide binding to MHC molecules is cited in the primary literature and available online.
Data analysis
Custom scripts used for k-mer analysis, compiling netMHC output, and assembling immune orthogonal cliques are publicly available on GitHub at https://github.com/natepalmer/immune-orthogonal
